From head to toe: how to perform a skin self-exam
Skin cancer is the most common type of cancer, accounting for nearly half of all cancers in the United States. Skin cancer is also treatable when found early. Here are step-by-step instructions on how to perform a skin self-exam, which is best done in a well-lit room in front of a full-length mirror. Consider asking another person to help you with the exam, especially for those hard-to-see areas like your back and scalp.
Answers to burning questions about sunscreen
One way to determine what SPF is best for you is by using the following equation: Minutes to burn without sunscreen x SPF number = maximum sun exposure time. Sunscreen should be applied at least 30 minutes before going out into the sun in order to allow it time to absorb into your skin. It should also be applied generously and at least every two hours, or more often if you are swimming or perspiring.
Prostate cancer trial aims to reduce radiation treatments
VCU Massey Cancer Center has opened a Phase I clinical trial testing an innovative radiation therapy for patients with early stage prostate cancer that has the potential to drastically reduce treatment time. In comparison to the standard schedule of eight weeks of daily external beam radiation therapy, the new technique requires just four treatments, administered twice in the first week and twice in the fourth week.
MicroRNA study funded by National Institute of Justice
A collaborative team of cancer and forensic science researchers at Virginia Commonwealth University (VCU) and VCU Massey Cancer Center were awarded a two-year, $310,000 grant from the Office of Justice Programs, housed within the National Institute of Justice (NIJ), to study microRNAs. MicroRNAs are a recently discovered class of RNAs that play key roles in the regulation of gene expression.
New drug combination therapy developed to treat leukemia
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent.